Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8078291 | 0.91 | MTNR1A (0.46) | HTTKDM4EMAPTMAPK1MTNR1A | |
| SCHEMBL3054218 | 0.89 | HTT (0.49) | HTTKDM4EMAPTMAPK1MTNR1A | |
| SCHEMBL3048958 | 0.88 | HDAC6 (0.52) | HTTMTNR1AMTNR1BALDH1A1 | |
| SCHEMBL3054312 | 0.84 | ALDH1A1 (0.43) | KDM4EL3MBTL1SMN1; SMN2ALDH1A1EGFR | |
| SCHEMBL3057582 | 0.83 | HTT (0.46) | HTTKDM4EMAPTMAPK1MTNR1A | |
| SCHEMBL3060167 | 0.81 | SMN1; SMN2 (0.47) | HTTMAPTL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL8084507 | 0.79 | RXRA (0.47) | HTTKDM4EMAPTMAPK1MTNR1A | |
| SCHEMBL3058846 | 0.77 | MTNR1A (0.54) | HTTKDM4EMAPK1MTNR1AMTNR1B | |
| SCHEMBL3064510 | 0.77 | MTNR1A (0.54) | HTTKDM4EMAPK1MTNR1AMTNR1B | |
| SCHEMBL1719811 | 0.76 | MTNR1A (0.51) | KDM4EMTNR1AMTNR1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261710-A1 | HDAC Inhibitors | ARQULE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261710-A1 | HDAC Inhibitors | ARQULE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261710-A1 | HDAC Inhibitors | ARQULE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| EP-2190845-A2 | HDAC INHIBITORS | ArQule, Inc. (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009026446-A9 | HDAC INHIBITORS | ARQULE, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009026446-A9 | HDAC INHIBITORS | ARQULE, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009026446-A2 | HDAC INHIBITORS | ARQULE, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009026446-A2 | HDAC INHIBITORS | ARQULE, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261710-A1 | HDAC Inhibitors | HDAC5, HDAC1, HDAC4 | HTT 296/4885KDM4E 117/4885MAPT 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.